Product
TAK-951
Aliases
TAK-951 Placebo
3 clinical trials
3 indications
Indication
Healthy VolunteerIndication
Postoperative Nausea and Vomiting (PONV)Indication
Healthy Control ParticipantsClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-951 in Healthy Subjects Following Intravenous AdministrationStatus: Completed, Estimated PCD: 2021-05-16
Clinical trial
A Randomized Double-Blind, Sponsor-Open, Double-Dummy, Proof of Concept Phase 2 Study to Evaluate the Efficacy and Safety of TAK-951 Versus Ondansetron in the Prophylaxis of Postoperative Nausea and Vomiting in High-Risk SubjectsStatus: Completed, Estimated PCD: 2022-03-07
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Three-part Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-951 in Healthy SubjectsStatus: Completed, Estimated PCD: 2020-11-02